ストックスクリーナーアプリを入手
1.82
1.68%
0.03
前日終値:
$1.79
開ける：
$1.82
24時間の取引高:
415.40K
Relative Volume:
0.64
時価総額：
$48.63M
収益：
-
当期純損益:
$-21.24M
株価収益率:
-2.1721
EPS:
-0.8379
ネットキャッシュフロー:
$-22.47M
1週間 パフォーマンス:
+26.83%
1か月 パフォーマンス:
-22.88%
6か月 パフォーマンス:
-63.82%
1年 パフォーマンス:
-85.84%
1日の値動き範囲:
$1.75
$1.92
1週間の範囲:
$1.36
$1.92
52週間の値動き範囲:
$1.14
$13.51
Skye Bioscience Inc Stock (SKYE) Company Profile
名前
Skye Bioscience Inc
セクター
電話
(858) 410-0266
住所
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
SKYE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.255 | 398.00M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.99 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1685 | 343.35M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
JUNE
Dhandho Junoon Etf
|
10.76 | 215.97M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.64 | 126.17M | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-09-30 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-09 | 開始されました | Craig Hallum | Buy |
| 2024-05-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-04-12 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Skye Bioscience Inc (SKYE) 最新ニュース
Skye Bioscience (SKYE) Grants Stock Options to New Employee | SK - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Skye Bioscience Board Approves 19,000 Share Options Grant Under 2024 Inducement Plan - Stock Titan
Skye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive Plan - Nasdaq
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com
SIMPLY BETTER BRANDS ANNOUNCES RESULTS FOR FISCAL 2024, HIGHLIGHTING 77% INCREASE IN TRUBAR™ REVENUE, AND CORPORATE NAME CHANGE TO TRUBAR INC. - The Globe and Mail
William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat
(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com
SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World
William Blair Predicts Skye Bioscience Q1 Earnings - Defense World
Brokers Offer Predictions for Skye Bioscience Q1 Earnings - Defense World
Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60 - Defense World
Brokers Issue Forecasts for Skye Bioscience Q2 Earnings - Defense World
A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha
Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize
Skye Bioscience reports promising obesity treatment study By Investing.com - Investing.com South Africa
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga
Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium - GuruFocus
Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga
Skye Bioscience soars after experimental weight-loss drug shows promise in mice - TradingView
Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga
Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - marketscreener.com
Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss R - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab - GuruFocus
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model | SKYE Stock News - GuruFocus
Skye Bioscience reports promising obesity treatment study - Investing.com
Skye Bioscience Demonstrates Over 30% Weight Loss with - GlobeNewswire
Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - StreetInsider
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - markets.businessinsider.com
Revolutionary Obesity Drug Combo Shows 30% Weight Loss Success in Latest Trial Data - Stock Titan
Skye Bioscience to Conduct Meetings at Piper Sandler Conference - GuruFocus
Major Obesity Drug Developer Skye Bio Takes Center Stage at Prestigious Investor Conference - Stock Titan
Skye Bioscience (NASDAQ:SKYE) Shares Down 50.8% – Here’s Why - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Down 50.8% – What’s Next? - Defense World
Skye Bioscience, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsSKYE - ACCESS Newswire
Let's Tokyo! WestJet bolsters connectivity between Calgary and Japan with new daily year-round service - The Globe and Mail
VOO ETF News, 4/4/2025 - The Globe and Mail
Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World
Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.00 Average Price Target from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript - MSN
Skye Bioscience (NASDAQ:SKYE) Receives Outperform Rating from William Blair - MarketBeat
Skye Bioscience promotes Tu Diep to COO post - The Pharma Letter
Skye Bioscience Inc (SKYE) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):